Immortality
A few months ago, a paper was published in the International Journal of Epidemiology that caused a sensation in it’s home country – Denmark. Using registry data, and the diagnosis of non-melanomatous skin cancer as a proxy for…
Miracle Drug – Part 2
In a previous post, we discussed the dangers of subgroup analyses. Specifically, performing increasing numbers of post-hoc subgroup analyses increases the risk of a type 1 error while the inevitable reduction in numbers tested in subgroup analyses decreases…
Miracle Drug?
The above figure compares long term survival in a subgroup of a trial that was published in Circulation in 1980. This was a randomized controlled trial of just over 1000 patients with known cardiovascular disease who were treated with medical…